These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
161 related items for PubMed ID: 2459016
1. Clinical pharmacology and mode of action of a new antithrombotic compound: Defibrotide. Ulutin ON, Cizmeci G, Balkuv-Ulutin S. Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(1-2):177-80. PubMed ID: 2459016 [Abstract] [Full Text] [Related]
5. Defibrotide inhibits platelet activation by cathepsin G released from stimulated polymorphonuclear leukocytes. Evangelista V, Piccardoni P, de Gaetano G, Cerletti C. Thromb Haemost; 1992 Jun 01; 67(6):660-4. PubMed ID: 1509406 [Abstract] [Full Text] [Related]
10. An integrated view of the activities of defibrotide. Pescador R, Porta R, Ferro L. Semin Thromb Hemost; 1996 Jun 01; 22 Suppl 1():71-5. PubMed ID: 8807733 [Abstract] [Full Text] [Related]
11. The fibrinolytic mechanism of defibrotide: effect of defibrotide on plasmin activity. Echart CL, Graziadio B, Somaini S, Ferro LI, Richardson PG, Fareed J, Iacobelli M. Blood Coagul Fibrinolysis; 2009 Dec 01; 20(8):627-34. PubMed ID: 19809307 [Abstract] [Full Text] [Related]
12. Are increased ATP blood levels responsible for PGI2 release from endothelium? Salari PC, Marni A, Parisé M, Calvani AB, Spaggiari PG, Gaja G, Ferrero ME. Int J Tissue React; 1991 Dec 01; 13(4):219-23. PubMed ID: 1668237 [Abstract] [Full Text] [Related]
13. Improvement of walking distance by defibrotide in patients with intermittent claudication--results of a randomized, placebo-controlled study (the DICLIS study). Defibrotide Intermittent CLaudication Italian Study. Violi F, Marubini E, Coccheri S, Nenci GG. Thromb Haemost; 2000 May 01; 83(5):672-7. PubMed ID: 10823260 [Abstract] [Full Text] [Related]
15. Physical and pharmacologic manipulation of the vascular system as measured by the release of TFPI and other mediators of antithrombotic actions. Hoppensteadt DA, Jeske W, Fareed J, Nicolaides AN. Int Angiol; 1996 Mar 01; 15(1):39-46. PubMed ID: 8739535 [Abstract] [Full Text] [Related]
18. Defibrotide: an overview of clinical pharmacology and early clinical studies. Cornelli U, Nazzari M. Semin Thromb Hemost; 1988 Mar 01; 14 Suppl():64-70. PubMed ID: 3057638 [No Abstract] [Full Text] [Related]
19. A double-blind, multicenter, placebo-controlled, dose comparison study of orally administered defibrotide: preliminary results in patients with peripheral arterial disease. Strano A, Fareed J, Sabbá C, Albano O, Allegra C, Carlizza A, Binaghi F, Fronteddu F, Del Guercio R, Arpaia MR. Semin Thromb Hemost; 1991 Mar 01; 17 Suppl 2():228-34. PubMed ID: 1948094 [Abstract] [Full Text] [Related]
20. Acute effects of defibrotide, an experimental antithrombotic agent, on fibrinolysis and blood prostanoids in man. Coccheri S, Biagi G, Legnani C, Bianchini B, Grauso F. Eur J Clin Pharmacol; 1988 Mar 01; 35(2):151-6. PubMed ID: 3191933 [Abstract] [Full Text] [Related] Page: [Next] [New Search]